Quantitative Drug Metabolism with Accelerator Mass Spectrometry

Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications

Volumn , Issue , 2011, Pages 525-566

  Vogel, John S ^a   Lohstroh, Peter ^a   Keck, Brad ^a   Dueker, Stephen R ^a  

^a Vitalea Science   (United States)

Author keywords

AMS metabolite studies, clinical aspects assuring that no unaccounted sources of 14C or carbon enter a defined sample; LC AMS analysis of drug metabolites; Quantitative drug metabolism with accelerator mass spectrometry (AMS) quantifying concentrations of metabolites in humans

Indexed keywords

EID: 84886550075     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929278.ch16     Document Type: Chapter

References (93)

1. Baillie T, Cayen M, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol 182 (3): 188-196 (2002).
2. Barker J, and Garner RC. Biomedical applications of accelerator mass spectrometry-Isotope measurements at the level of the atom. Rapid Commum Mass Spectrom 1999; 13(4): 285-23.
3. Baxter M, Castle L, Crews HM, Rose M, Garner C, Lappin G, and Leong D. A sensitive method for the determination of chlorine-36 in foods using accelerator mass spectrometry. Food Additives and Contaminants Part a-Chem Anal Control Expos Risk Assess 2009; 26(1): 139-144.
4. Bennett CL, Beukens RP, Clover MR, Gove HE, Liebert RB, Litherland AE, Purser KH, and Sondheim WE. Radiocarbon dating using electrostatic accelerators: Negative-ions provide key. Science 1977; 198 (4316): 508-510.
5. Bennett JS, Bell DW, Buchholz BA, Kwok ESC, Vogel JS, and Morton TH. Accelerator mass spectrometry for assaying irreversible covalent modification of an enzyme by acetoacetic ester. In J Mass Spectrom 1998; 180: 185-193.
6. Bronk Ramsey C, and Hedges REM. Hybrid ion sources: Radiocarbon measurements form microgram to milligram. Nucl Instrum Methods Phys Res 1997; B 123: 539-545.
7. Brown K, Dingley KH, Turteltaub KW. Accelerator mass spectrometry for biomedical research. Methods Enzymol 2005; 402: 423-434.
8. Buchholz, BA, Freeman S, Haack KW, and Vogel JS. Tips and traps in the C-14 bio-AMS Preparation laboratory. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms 2000; 172: 404-408.
9. Buchholz BA, Fultz E, Haack KW, Vogel JS, Gilman SD, Gee SJ, Hammock BD, Hui X, Wester RC, and Maibach HI. HPLC-accelerator MS measurement of atrazine metabolites in human urine aftger dermal exposure. Anal Chem 1999; 71 (16): 3519-3525.
10. Cheung BWY, Cartier LL, Russile HQ, Sawchuk RJ. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fund Clin Pharmacol 2005; 19(3): 347-354.
11. Chaiarappa-Zucca ML, Finkel RC, Martinelli RE, McAnianch JE, Nelson DO, Turteltaub KW. Measurement of beryllium in biological samples by accelerator mass spectrometry: Applications for studdying chronic beryllium disease. Chem Res Toxicol 2004; 17(12): 1614-1620.
12. Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res 2008; 36: e100-110.
13. Colizza, K, Awad M, Kamel A. Metabolism, pharmacokinetics, and excretion of the substance preceptor antagonist CP-122,721 in humans: Structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by highperformance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. Drug Metab Dispos 2007; 35(6): 884-897.
14. Creek MR, Frantz CE, Fultz E, Haack K, Redwine K, Shen N, Turteltaub KW, Vogel JS. 14C AMS quantification of biomolecular interactions using microbore and plate separations. Nucl Instrum Methods 1994; B92: 454-458.
15. Creek, MR, Mani C, Vogel JS, Turteltaub KW. Tissue distribution and macromolecular binding of extremely low doses of C-14-benzene in B6C3F1 mice. Carcinogenesis 1997; 18(12): 2421-2427.
16. Crosignani A, Setchell KDR, Invernizzi P, Larghi A, Rodrigues CMP, Podda M. Clinical pharmacokinetics of therapeutic bile acids. Cliln Pharmacokinet 1996; 30(5): 333-358.
17. Cupid BC, Lightfoot TJ, Russell D, Gant SJ, Turner PC, Dingley KH, Curtis KD, Leveson SH, Turteltaub KW, Garner RC. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem Toxicol 2004; 42(4): 559-569.
18. Cuyckens F, Koppen V, Kembuegler R, Leclercq L. Improved liquid chromatography-Online radioactivity detection for metabolite profiling. J Chromatogr A 2008; 1209 (1-2): 128-135.
19. DeGregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW. Accelerator mass spectrometry allows for celluar quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol 2006; 57(3): 335-342.
20. Denk E, Hillegonds D, Hurrell RF, Vogel J, Fattinger K, Hauselmann HJ, Kraenzlin M, Walczyk T. Evaluation of (41) calcium as a new approach to assess changes in bone metabolism: Effect of a bisphosphonate in tervention in postmenopausal women with low bone mass. J Bone Mineral Res 2007; 22(10): 1518-1525.
21. Denk E, Hillegonds D, Vogel J, Synal A, Geppert C, Wendt K, Fattinger K, Hennessy C, Berglund M,Hurrell RF, Walczyk T. Labeling the human skeleton with Ca-41 to assess changes in bone calcium metabolism. Anal Bioanal Chem 2006; 386(6): 1587-1602.
22. Dingley KH, Curtis KD, Nowell S, Felton JS, Lang NP, Turteltaub KW. DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relvant dose of 2-amino-1methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol Biomakers Prev 1999; 8(6): 507-512.
23. Dingley KH, Freeman S, Nelson DO, Garner RC, Turteltuab KW. Covalent binding of 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline to albumin and hemoglobin at environmentally relevant doses-Comparison of human subjects and F344 rats. Drug Metab Dispos 1998a; 26(8): 825-828.
24. Dingley KH, Roberts ML, Velsok CA, Turteltaub KW. Attomole detection of 3H in biological samples using accelerator mass spectrometry: Application in low-dose, dual-isotope tracer studies in conjunction with C-14 accelerator mass spectrometry. Chem Res Toxicol 1998b; 11(10)1217-1222.
25. DingleyKH, Ubick EA, Chiarappa-ZuccaML, Nowell-S,Abel S, Ebeler SE, Mitchell AE, Burns SA, Steinberg FM, Clifford AJ. Effect to dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and 1Q and phase II hepatic enzyhmes. Nutr Cancer In J 2003; 46(2): 212-221.
26. Dueker SR, Lin Y, Buchholz BA, Schneider PD, Lame MW, Segall HJ Vogel JS Clifford AJ. Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. J Lipid Res 2000; 41(11): 1709-1800.
27. Ebeler SE, Dingley KH, Ubick E, Abel S, Mitchell AE, Burns SA, Steinberg FM, Clifford AJ. Animal models and analytical approaches for understanding the relationships between wine and cancer. Drugs Exper Clin Res 2005; 31(1): 19-27.
28. Fallon SJ, Guilderson TP, Brown TA. CAMS/LLNL ion source efficiency revisited. Nucl Instrum Methods Phys Sect B Beam Interact Mater Atoms 2007; 259 (1): 106-110.
29. Flarakos J, Liberman RG, Tannenbaum SR, Skiper PI. Intergration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal Chem 2008; 80(13): 5079-5085.
30. Flarend RE, Hem SL, White JL, Elmore D, Sucknow MA, Rudy AC, Dandashli EA. In-vivo absorption of aluminum-containing vaccine adjuvants using A1-26. Vaccine 1997; 15(12-13): 1314-1318.
31. Garner RC, Goris I, Laenen AA, Vanhoutte E, Meuldermans W, Gregory S, Garner JV, Leong D, Whattam M, Calam A, Snel CA. Evaluation of accelerator mass spectrometry in human mass balance and pharmacokinetic study-Experience with 14Clabeled (R)-6-[amino(4-chlorophenyl)(1-methy-1H-imidazol-5-yl)]methyl-4-(3-chlorophenyl)-1-methy-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Disposl 2002; 30(7): 823-830.
32. Garner RC, Lightfoot TJ, Cupid BC, Russell D, Coxhead JM, Kutschera W, Priller A, Rom W, Steier P, Alexander DJ, Leveson SH, Dingley KH, Mauthe RJ, Turteltaub KW. Comparative biotransformation studies of MelQx and PhIP in animal models and humans. Cancer Lett 1999; 143(2): 161-165.
33. Gilman SD, Gee SJ, Hammock BD, Vogel JS, Haack K, Buchholz BA, Freeman SP, Wester RC, Hui X, Maibach HI. Analytical performance of accelerator mass spectrometry metabolites in human urine. Anal Chem 1998; 70(16): 3463-3469.
34. Guengerich FP. Introduction: Human metabolites in ssfety testing (MIST) issue. Chem Res Toxicol 2009; 22(2): 237-238.
35. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 1981; 29(3): 408-413.
36. Hickenbottom SJ, Limke SL, Dueker SR, Y, Follett JR, Carkeet C, Buchholz BA, Vogel JS, Clilfford AJ. Dual isotope test for assessing beta-carotene cleavage to vitamin A in humans. Eur J Nutr 2002; 41(4): 141-147.
37. Ho CC, de Moura FF, Kim SH, Burri BJ, Clifford AJ. A minute dose of 14C-{beta}-carotene is absorbed and converted to retinoids in humans. J Nutr 2009; 139 (8): 1480-1486.
38. Hop C, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 1998; 87(7): 901-903.
39. Kamen M. Tracers. Sci Am 1949; 180(2): 30-40.
40. Kautiainen A, Vogel JS, Turteltaub KW. Dose-dependent binding of trichloroethylene to hepatic DNA and protein at low doses in mice. Chem-Biol Interact 1997; 106 (2): 109-121.
41. Keck BD, Ognibene T, Vogel JS. Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2010; 2(3): 469-485.
42. Kim SH, Kelly PB, Clifford AJ. Accelerator mass spectrometry targets of submilligram carbonaceous samples using the high-throughput Zn reduction method. Anal Chem 2009; 81(41): 5949-5954.
43. Kustschera W. Progress in isotope analysis at ultra-trace level by AMS. Int J Mass Spectrom 2005; 242(2-3): 145-160.
44. Lang NP, Nowell S, Malfatti MA, Kulp KS, Knize MG, Davis C, Massengill J, Williams S, MacLeod S, Dingely KH, Felton JS, Turteltaub KW. In vivo human metabolism of 2-C-14 2-amino-1-methy-6-phenylimidazo-4,5-b pyridine (PhIP). Cancer Letth 1999; 143(2): 135-138.
45. Lappin G, Garner RC, Meyers T, Powell J, Varely P. Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. J Pharm Biomed Anal 2006; 41(4): 1299-1302.
46. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: Recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxico 2008; 4 (8): 1021-1033.
47. Lemke SL, Dueker SR, Follett JR, Lin YM, Carkeet C, Buchholz BA, Vogel JS, Clifford AJ. Absorption and retinol equivalence of beta-carotene in humans is influjenced by dietary vitaman A intake. J Lipid Res 2003; 44(8): 1591-1600.
48. Liberman RG, Skipper PL, Prakash C, Shaffer CL, Flarakos J, Tannenbaum SR. BEAMS Lab: Novel approaches to finding a balance between throughput and sensitivity. Nucl Instrum Methods Phys Res Sect Beam Interact Mater Atoms 2007; 259(1): 773-778.
49. Liberman RG, Tannenbaum SR, Hughey BJ, Shefer RE, Klinkowstein RE, Prakash C, Harriman SP, Skipper PL. An interface for direct analysis of C-14 in nonvolatile samples by accelerator mass spectrometry. Anal Chem 2004; 76(2): 328-334.
50. Lightfoot TJ, Coxhead JM, Cupid BC, Nicholson S, Garner RC. Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine and benzo[a]pyrene. Mutat Res 2000; 472(1-2): 119-17.
51. Lin YM, Dueker SR, Follett JR, Fadel JG, Arjomand A, Schneider PD, Miller JW, Green R, Buchholz BA, Vogel JS, Phair RD, Clifford AJ. Quantitation of in vivo human folate metabolism. Am J Clin Nutr 2004; 80(3): 680-691.
52. Mani C, Freeman S, Nelson DO, Vogel JS, Turteltaub KW. Species and strain comparisons in the macromolecular binding of extremely low doses of C-14 benezene in rodents, using accelerator mass spectrometry. Toxicol Appl Pharmacol 1999; 159(2): 83-90.
53. Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, Smith LL, White INH. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003; 63(23): 8461-8465.
54. Martin EA, Carthew P, White INH, Heydon RT, Gaskell M, Mauthe RJ, Turteltaub KW, Smith LL. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis 1997; 18 (11): 2209-2215.
55. Mauthe RJ, Dingley KH, Leveson SH, Freeman S, Turesky RJ, Garner RC, Turteltaub KW. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 1999; 80(4): 539-545.
56. McIntyre CP, Sylva SP, Roberts ML, Gas chromatograph-combustion system for C-14-accelerator mass spectrometry. Anal Chem 2009; 81(15): 6422-6428.
57. Middleton R., Survey of negative-ion sources for tandem accelerators. Nucl Instrum Methods 1974; 122(1-2): 35-43.
58. Middleton R. A review of ion sources for accelerator mass spectrometry. Nucl Instrum Methods Phys Res B Beam Interact Mater Atoms (Netherlands) 1984; 233 (2): 193-199.
59. Miyashita M, Presley JM, Buchholz BA, Lam KS, Lee YM, Vogel JS, Hammock BD. Attomole level protein sequencing by Edman degradation coupled with accelerator mass spectrometry. Proc Natl Acad Sci U.S.A. 2001; 98(8): 4403-4408.
60. Nassar AEF, Bjorge SM, Lee DY. On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal Chem 2003; 75(4) 785-790.
61. Nelson DE, Korteling RG, Stott WR. Carbon-14: Direct detection at natural concentrations. Science 1977; 198(4316): 507-508.
62. Nobilis M, Kunes J, Kopecky J, Kvetina J, Svoboda Z, Sladkova K, Vorterl J. Highperformance liquid chromatographic determination of ursodeoxycholic acid after solid phase extraction of blood serum and detection-oriented derivatization. J Pharm Biomed Anal 2001; 24(5-6): 937-946.
63. Ognibene TJ, Bench G, Brown TA, Vogel JS. Ion-optics calculations and preliminary precision estimates of the gas-capable ion source for the 1-MV LLNL BioAMS spectrometer. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms 2007; 259(1): 100-105.
64. Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of C-14 via accelerator mass spectrometry. Anal Chem 2003; 75(9): 2192-2196.
65. Prakash C, Shaffer CL, Tremaine LM, Liberman RG, Skipper PL, Flarakos J, Tannenbaum SR. Applications of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 1, 226-231 (2007).
66. Riad LE, Chan KK, Sawchuk RJ. Determination of the relative formation and elimination clearance of 2 major carbamazepine metabolites in humans-A comparison between traditional and pooled sample analysis. Pharm Res 1991; 8(4): 541-543.
67. Rouwenhorst RJ, Jzn JF, Scheffers WA, Vandijken JP. Determination of proteinconcentration by total organic-carbon analysis. J Biochem Biophys Methods 1991; 22(2): 119-128.
68. Schoenheimer R, Rittenberg D, Foster GL, Keston A, Ranter S. The application of the nitrogen isotope N-15 for the study of protein metabolism. Science 1938; 88: 599-600.
69. Schulze-König T, Dueker SR, Giacomo J, Suter M, Vogel JS, Synal HA. BioMICADAS: Compact next generation AMS system for pharmaceutical science. Nucl Instrum Methods 2010; B268: 891-894.
70. Skog G. The single stage AMS machine at Lund University: Status report. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms 2007; 259(1): 1-6.
71. Synal HA, Dobeli M, Jacab S, Stocker M, Suter M. Radiocarbon AMS towards its lowenergy limits. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms 2004; 223: 339-345.
72. Synal HA, Stocker M, Suter M. MICADAS: A new compact radiocarbon AMS system. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms 2007; 259(1): 7-13.
73. Taylor RE, Long A, Kra RS. Radiocarbon after Four Decades: An Interdisciplinary perspective, Springer-Verlag, New York, 1992.
74. Tiller PR, Yu S, Castro-Perez J, Fillgrove KL, Baillie TA. High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-offlight system as a " first-line" approach for metabolite indentification studies. Rapid Commun Mass Spectrom 2008; 22(7)1053-1061.
75. TurteltaubKW,DingleyKH,CurtisKD,MalfattiMA,TureskyRJ,GarnerRC, FeltonJS, Lang NP. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett 1999; 143(2): 149-155.
76. Turtelaub KW, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, Finkel RC, Nelson DE, Proctor ID, Davis JC. Accelerator mass-spectrometry in biomedical dosimetry-Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci USA 1990; 87 (14): 5288-5292.
77. Turteltaub KW, Frantz CE, Creek MR, Vogel JS, Shen N, Fultz E. DNA-adducts in model systems and humans J Cell Biochem 1993; S17: 138-148.
78. Turteltaub KW, Mauthe RJ, Dingley KH, Vogel JS, Frantz CE, Garner RC, Shen N. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res Fun Mol Mech Mutagen 1997; 376(1-2): 243-252.
79. US FDA. Centre for Drug Evaluation and Research. Guidance for industry: Bioanalytical method validation. UCM070107 (2001).
80. US FDA. Centre for Drug Evaluation and Research. Guidance for Industry: Safety Testing of Drug Metabolites. UCM065014 (2008).
81. US FDA. Guidance for industry: ICH Q2B validation of analytical procedures: methodology CDER/CBER. (1996).
82. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 1992; 34: 344-350.
83. Vogel JS, Grant PG, Buchholz BA, Dingley K, Turteltaub KW. Attomole quantitation of protein separations with accelerator mass spectrometry. Electrophosesis 2001; 22 (10): 2037-2045.
84. Vogel JS, Love AH (2005). Quantitating isotopic molecular labels with accelerator mass spectrometry. Meth Enzm 402: 402-422.
85. Vogel JS, Nelson DE, Southon JR. Background levels in an AMS system.Radiocarbon 1987; 29: 215-222.
86. Vogel JS, OgnibeneT, Palmblad M, Reimer P. Counting statistics and ion interval density in AMS. Radiocarbon 2004; 46(3): 1103-1109.
87. Vogel JS, Southon JR, Nelaon DE, Brown TA. Performance of catalytically condensed carbon for use in accelerator mass spectrometry. Nucl Instrum Methods 1984; B5: 289-293.
88. Vuong LT, Lohstroh P, Blood A, Vasquez H, Vogel JS. Applying AMS in neonatal research and care. J Isotope Labelled Comp Radiopharm. 2010; 53: 352-354.
89. White INH, Martin EA, Mauthel RJ, Vogel JS, Turteltaub, KW, and Smith LL. Comparisons of the binding of C-14 radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem-Biol Interact 1997; 106(2): 149-160.
90. Xu XM, Trumbore SE, Zheng SH, Southon JR, McDuffee KE, Luttgen M, Liu JC. Modifying a sealed tube zinc reduction method for preparation of AMS graphite targets: Reducing background and attaining high precision. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms 2007; 259(1): 320-329.
91. Young GC, Corless S, Felgate CC, Colthup PV. Comparison of a 250kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer-Fitness for purpose in bioanalysis. Rapid Commun Mass Spectrom 2008; 22 (24): 4035-4042.
92. Zhu MS, Zhao WP, Vazquez N, Mitroka JG. Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: Method validation and application. J Pharm Biomed Anal 2005; 39(1-2): 233-245.
93. Performance evaluation of the new ams system at Accium Biosciences